Carregant...
Delay of Alternative Antiviral Therapy and Poor Outcomes of Acyclovir-Resistant Herpes Simplex Virus Infections in Recipients of Allogeneic Stem Cell Transplant
Acyclovir is commonly used to prevent and treat herpes simplex virus (HSV) reactivation after hematopoietic cell transplant (HCT), and only few reports have been published on acyclovir-resistant HSV in HCT recipients. We reviewed the medical records of patients with a microbiologic diagnosis of acyc...
Guardat en:
| Publicat a: | Transpl Int |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5948153/ https://ncbi.nlm.nih.gov/pubmed/29464765 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/tri.13142 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|